Condition: Cervical Intraepithelial Neoplasia · Cervical Squamous Cell Carcinoma In Situ · Cervical Squamous Intraepithelial Neoplasia 2 · Sponsor: Jonsson Comprehensive Cancer Center
This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
This description comes directly from the study's public registry record.
Maria Garcia-Jimenez, MD · 310 209-0618 · MGarciaJimenez@mednet.ucla.edu
Rosleen Mala · 310 794-3879 · RMala@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| University of California at Los Angeles / Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04712851